Sana Biotechnology's Islet Cell Transplantation Study Shows Positive Results for Type 1 Diabetes Treatment.

Sana Biotechnology announced continued positive clinical results from a Type 1 Diabetes study of islet cell transplantation without immunosuppression. The study found that HIP-modified islets are safe, evade detection by the immune system, survive long-term, and continue to produce insulin. C-peptide levels at 14 months were comparable to the initial six months, highlighting the importance of improved glycemic control on islet function. Sana plans to file an IND application for SC451, a HIP-modified, stem cell-derived therapy, and initiate a Phase 1 trial as early as this year.